doi: 10.1016/j.isci.2019.05.030 Wu YR, Shi XY, Ma CY, Zhang Y, Xu RX, Li JJ
How PlexusDx Supports a More Personalized Approach PlexusDx's Precision Peptide Genetic Test may help provide context by revealing predispositions in GIPR (rs1800437), and other glucose-sensing variants
North America is dominating the GLP-1 analogues market, supported by a high prevalence of type 2 diabetes and obesity, strong healthcare infrastructure, and rapid adoption of innovative therapies
The relatively new drugs the first being approved by the Food and Drug Administration (FDA) in 2005 also signal a significant shift in how hospitals and health systems treat chronic conditions such as type 2 diabetes and heart disease
Because tirzepatide acts on two hormone pathways rather than one, some people notice stronger appetite suppression and fuller meals, as well as more pronounced nausea or digestive shifts right after a dose